BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/15/2022 9:40:09 AM | Browse: 572 | Download: 1600
 |
Received |
|
2021-10-09 14:24 |
|
Peer-Review Started |
|
2021-10-09 14:26 |
|
First Decision by Editorial Office Director |
|
2021-12-12 08:13 |
|
Return for Revision |
|
2021-12-12 08:13 |
|
Revised |
|
2022-01-04 11:11 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-02-14 05:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-02-16 07:29 |
|
Articles in Press |
|
2022-02-16 07:29 |
|
Edit the Manuscript by Language Editor |
|
2022-02-09 16:37 |
|
Typeset the Manuscript |
|
2022-04-01 07:31 |
|
Publish the Manuscript Online |
|
2022-04-15 09:40 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Jie Xu, Peng Zhang, Jin-Long Hu, Hong Liang, Yan-Yan Zhu, Yao Cui, Po Niu, Min Xu and Ming-Yue Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Henan Provincial Department of Science and Technology |
212102310047 |
|
| Corresponding Author |
Ming-Yue Liu, Doctor, MD, PhD, Chief Doctor, Department of Oncology, Henan Provincial People's Hospital, No.7 Weiwu road, Zhengzhou 450003, Henan Province, China. 1816160187@e.gzhu.edu.cn |
| Key Words |
Colorectal neoplasms; Microsatellite stable; Programmed cell death-1 inhibitor; Platelet-to-lymphocyte ratio; Regorafenib; Progression-free survival |
| Core Tip |
The use of regorafenib combined with programmed cell death-1 inhibitor in the treatment of refractory microsatellite stable colorectal cancer has contradictory results in some small-scale studies. The purpose of this paper is to analyze the real-world data of our center in the past 2 years so as to provide more treatment experience and reference for treatment selection. The progression-free survival and overall survival of patients with refractory microsatellite stable colorectal cancer treated with regorafenib combined with programmed cell death-1 inhibitor were analyzed retrospectively, and the safety and adverse reactions under different doses were reviewed. The platelet-to-lymphocyte ratio was found as a potential screening index for patients with prolonged progression-free survival. |
| Publish Date |
2022-04-15 09:40 |
| Citation |
Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the predictive value of platelet-to-lymphocyte ratio on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i4/920.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i4.920 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
